Results from two Phase III multi-country trials (ASPIRE and Ring) studying the 4-week slow-release dapivirine vaginal ring were released at the Conference on Retroviruses and Opportunistic Infection. The trials showed modest protection reducing rates of HIV acquisition by around one-third overall with greater effect in women over 21 who had higher adherence. Below, please find press releases, background information and other useful resources about the Ring and ASPIRE studies.
- International Partnership for Microbicides Press Release
- Microbicide Trials Network Press Release
- AVAC Press Release
- CAPRISA Press Release
- CONRAD Press Release
- IAVI Press Release
- ICWEA Press Release
- International HIV/AIDS Alliance Press Release
- NIAID Press Release
- Population Council Press Release
- SAMRC Press Release
- UNAIDS Press Release
- Click for the presentations of the ASPIRE and Ring Study results.
- AVAC hosted a post-CROI webinar with with Jared Baeten (MTN) and Zeda Rosenberg (IPM) where they presented their results and fielded questions from webinar participants; click here.
Materials from IPM and MTN
- Use of a Vaginal Ring Containing Dapivirine for HIV-1 Prevention in Women — New England Journal of Medicine
Highlighted News and Blogs
- Vaginal Ring Could Cut HIV Risk by 27-31 Percent — Scidev
- Innovative HIV Prevention Product for Women Could be New Tool in the Fight for an AIDS Free Generation — USAID Impact Blog
- Vaginal Ring Offers Partial HIV Protection — Health-E News
- Vaginal Rings Containing Antiretroviral Moderately Effective in Preventing HIV – but not in the youngest women — aidsmap
- A Vaginal Ring Could Prevent HIV, Two Huge Studies Just Found — BuzzFeed
- Drug-laced Vaginal Ring Succeeds Against HIV- Sometimes — Science
Download a PDF version of the table here.
To help understand these infographics, plesae see our Advocates' Guide to Statistical Terms.